Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Chronic Lymphocytic Leukemia
Related studies linked through entity extraction aliases.
Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)
- Status
- COMPLETED
- Phase
- PHASE1
Allo HSCT Using RIC for Hematological Diseases
- Status
- COMPLETED
- Phase
- PHASE2
A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304
- Status
- TERMINATED
- Phase
- PHASE2
A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor
- Status
- WITHDRAWN
- Phase
- PHASE1
Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi
- Status
- COMPLETED
- Phase
- PHASE2
Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Quality Improvement Approach to the Management of Chronic Lymphocytic Leukemia
- Status
- COMPLETED
- Phase
- NA
Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia
- Status
- TERMINATED
- Phase
- PHASE3
Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.
- Status
- WITHDRAWN
- Phase
- PHASE1
Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis
- Status
- COMPLETED
- Phase
- PHASE2
Clinical-biological Characteristics and Outcome of Chronic Lymphocytic Leukemia Under Ibrutinib-named Patient Program
- Status
- COMPLETED
- Phase
- N/A
Reduced Intensity Conditioning Transplant Using Haploidentical Donors
- Status
- COMPLETED
- Phase
- PHASE2
Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLL
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies
- Status
- COMPLETED
- Phase
- PHASE2
Cholecalciferol in Newly Diagnosed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia With Vitamin D Deficiency
- Status
- COMPLETED
- Phase
- NA
A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation
- Status
- COMPLETED
- Phase
- PHASE1
Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia
- Status
- COMPLETED
- Phase
- PHASE2
Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2